Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

Mene Pan­ga­los is dou­bling down on RNA-based tech­nolo­gies for his side of the As­traZeneca R&D ma­chine.

Just two months af­ter bring­ing a small ac­ti­vat­ing RNA (saR­NA) pro­gram in­to its fold, Pan­ga­los now has his eyes on Si­lence Ther­a­peu­tics’ small in­ter­fer­ing RNA (siR­NA) plat­form. Call­ing it an “ex­cit­ing new modal­i­ty” for the phar­ma gi­ant’s drug dis­cov­ery tool­box, As­traZeneca has shelled out $60 mil­lion in cash and pur­chased $20 mil­lion worth of Si­lence’s stock on the Lon­don ex­change.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.